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Due to the ubiquitous nature of porcine circovirus type 2 (PCV2) in the pig population and the increasing
use of PCV2 vaccines in breeding herds, the majority of dams have been exposed to field PCV2 or PCV2
vaccines, resulting in piglets with varied levels of passively acquired PCV2 maternal antibodies. The objective
of the current research was to investigate the influence of passively acquired anti-PCV2 antibodies on PCV2
vaccine efficacy. Sixty 26-day-old pigs were divided into four groups: vaccinated pigs with no maternal PCV2
antibodies at the time of vaccination (VAC-NEG; n 9), vaccinated pigs with maternal PCV2 antibodies at the
time of vaccination (VAC-POS; n  21), nonvaccinated pigs with no maternal antibodies at the time of
challenge (NVAC-CNEG; n  15), and nonvaccinated pigs with maternal antibodies at the time of challenge
(NVAC-CPOS; n  15). Vaccinations and challenges were performed on trial days 0 and 28, respectively,
according to group designation. The pigs were monitored for clinical signs of disease daily and weighed weekly,
and blood was collected weekly. All pigs were necropsied on trial day 49, and tissues were evaluated for
macroscopic and microscopic lesions. Serum was evaluated using PCV2 immunoglobulin G (IgG) and PCV2
IgM enzyme-linked immunosorbent assays, quantitative PCV2 PCR, and a serum PCV2 neutralizing antibody
test. In comparison to NVAC-CPOS pigs, VAC-POS animals had significantly (P < 0.01) less severe micro-
scopic PCV2-associated lymphoid lesions and significantly (P < 0.04) reduced PCV2 genomic copies in serum
following PCV2 challenge. These results indicate that vaccination with Suvaxyn PCV2 One Dose reduces
viremia and prevents microscopic lesions associated with PCV2 in the presence of maternal antibodies.
Porcine circovirus type 2 (PCV2) is a small, nonenveloped,
single-stranded DNA virus that is ubiquitous in the swine pop-
ulation (1). PCV2 continues to have a major economic impact
on the global swine industry. It has been associated with sys-
temic infection (1), respiratory disease (7, 8), enteritis (9),
reproductive failure (10, 13, 23), and porcine dermatitis and
nephropathy syndrome (20, 22). In order to combat the grow-
ing problems associated with PCV2-associated disease, several
vaccines were introduced into the U.S. market in 2006. Initial
reports on the efficacy of these products indicated that vacci-
nation is an effective tool to reduce PCV2-associated losses in
production systems (15).
Due to the combination of vaccine usage and the ubiquitous
nature of PCV2, the majority of females in breeding herds
have been exposed to field PCV2 or PCV2 vaccines, and their
piglets have varied levels of passively acquired PCV2 antibod-
ies. In a previous report, sows from six U.S. breeding herds
were tested for the presence of PCV2 antibodies, and 50 to
80% of dams from the herds had sample-to-positive (S/P)
ratios greater then 0.6, 15 to 42% had S/P ratios between 0.2
and 0.6, and 0 to 8% were seronegative (18). This study also
indicated that maternal antibodies decay over a wide window
of time (2 to 15 weeks of age) in growing pigs within a popu-
lation, depending on the initial concentration of maternal an-
tibodies (18).
Although maternal antibodies against PCV2 are present at
various levels in the swine population, their ability to com-
pletely prevent infection has not been proven. In a study by
McKeown et al., 12-day-old commercial pigs with various lev-
els of maternal antibodies were infected with a PCV2 infec-
tious clone (11). Results indicated that high levels of maternal
antibodies provided some protection (reduced peak viremia
levels) but did not completely prevent infection. In animals
with low levels of maternal antibodies, protection was not
conferred (11). These results agreed with a study by Ostanello
et al. which suggested that while maternal antibody levels were
related to the development of PCV2-associated disease, they
were unable to prevent clinically silent PCV2 infections (19).
While vaccines have been shown to be effective when used
on pigs with no or low levels of passively acquired PCV2
antibodies, the effect of high levels of maternal antibodies on
PCV2 vaccination remains unknown. Veterinary practitioners
have raised concerns that pigs with detectable levels of pas-
sively acquired PCV2 antibodies may not develop a protective
immune response to PCV2 vaccines. The study described in
this report was designed to investigate the influence of pas-
sively acquired PCV2 antibodies on PCV2 vaccine efficacy,
using one of the commercial PCV2 vaccines available in the
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United States. The hypothesis of the study was that vaccination
in the presence of maternal antibody would result in protection
(reduced PCV2 genomic copies and reduced PCV2-associated
microscopic lesions) of pigs following challenge with PCV2.
MATERIALS AND METHODS
Experimental design. Sixty 26- to 28-day-old, PCV2 PCR-negative piglets with
various levels of passively acquired PCV2 antibody levels, as determined with a
PCV2 open reading frame 2-based enzyme-linked immunosorbent assay
(ELISA) (12), were blocked by PCV2 antibody level and randomly divided into
four groups: vaccinated pigs with negative PCV2 ELISA S/P ratios at the time of
vaccination (VAC-NEG; n  9), vaccinated pigs with positive PCV2 ELISA S/P
ratios at the time of vaccination (VAC-POS; n  21), nonvaccinated pigs with
negative PCV2 ELISA S/P ratios at the time of challenge (NVAC-CNEG; n 
15), and nonvaccinated pigs with positive PCV2 ELISA S/P ratios at the time of
challenge (NVAC-CPOS; n  15). Vaccinations and challenges were performed
on trial days 0 and 28, respectively, according to group designation (Table 1). The
pigs were monitored for clinical signs of disease daily and weighed and bled
weekly. On trial day 49 (21 days after PCV2 challenge [DPC]), all pigs were
necropsied and the tissues were evaluated for macroscopic and microscopic
lesions. The experimental protocol was approved by the Iowa State University
Institutional Animal Care and Use Committee.
Animals and housing. Colostrum-fed, cross-bred, specific-pathogen-free pigs
were purchased from a herd that is routinely tested for major swine pathogens
and known to be free of porcine reproductive and respiratory syndrome virus,
swine influenza virus, and Mycoplasma hyopneumoniae. The farm was positive for
PCV2 as determined by serology on sows; however, PCV2-associated disease was
not present in the source farm or the offspring from this farm. The pigs were
weaned at 2 weeks of age and transported to the Livestock Infectious Disease
Isolation Facility at Iowa State University, Ames. The pigs were bled on arrival
to confirm PCV2 PCR-negative status. On the day of delivery, the pigs were
randomly assigned to one of two rooms, each containing six 2.5- by 3.6-m raised
wire decks equipped with one nipple drinker and one self-feeder.
Vaccination. On trial day zero, nine pigs with PCV2 ELISA S/P ratios below
0.3 (VAC-NEG) and 21 pigs with S/P ratios equal to or higher than 0.3 (VAC-
POS) received 2 ml of a commercially available killed PCV1-2 chimeric vaccine
(Suvaxyn PCV2 One Dose; Fort Dodge Animal Health, Inc., Fort Dodge, IA).
The injection was given intramuscularly into the right neck according to the
manufacturer’s instructions.
Inoculation. Each pig received 4 ml (1 ml intramuscularly and 3 ml intrana-
sally) of PCV2 inoculum. The inoculum used was the fifth passage of PCV2
isolate 40895 (2, 3) at an approximate concentration of 104.7 50% tissue culture
infective doses.
Serology. Blood samples were collected upon arrival of the pigs at the research
facility and weekly thereafter until necropsy. The serum was tested by the PCV2
open reading frame 2-based immunoglobulin G (IgG) ELISA (12). Samples
were considered positive if the calculated S/P ratio was 0.3 or greater. A cutoff of
0.3 was used based on Iowa State University Laboratory protocols and was
previously determined (unpublished data) to provide optimal sensitivity and
specificity for the assay.
Samples were also tested by the Ingezim PCV2 ELISA IgM assay (Ingenasa,
Madrid, Spain). The ELISA cutoff value was determined by multiplying by 0.4
the average optical density at 450 nm of the IgM-positive control wells. A
fluorescence focus neutralization assay was done on trial day 0, 24, and 28 serum
samples in order to determine the presence of neutralizing antibodies (NAs)
against PCV2 according to the standard Iowa State University Veterinary Diag-
nostic Laboratory operating protocol. PCV2 isolate ISU-98-15237 was used in
this assay.
Clinical evaluation. Following PCV2 inoculation, the pigs were monitored
daily and scored for severity of clinical respiratory disease, using scores ranging
from 0 (normal) to 6 (severe dyspnea and abdominal breathing) (6). In addition,
pigs were evaluated daily for clinical signs, including sneezing, ranging from 0 (no
sneezing) to 3 (severe persistent sneezing), and jaundice. Rectal temperatures,
wasting, and behavioral changes such as lethargy were recorded daily. The pigs
were weighed on the day of vaccination and weekly thereafter until necropsy.
PCV2 DNA quantification. DNA extraction from serum samples collected on
trial days 0, 7, 14, 21, 28, 35, 42, and 48 was performed using the QIAamp DNA
Mini kit (Qiagen, Valencia, CA). DNA extracts were used for quantification of
PCV2 genomic DNA copy numbers by real-time PCR as described previously
(17).
Necropsy. All pigs were humanely euthanized by phenobarbital overdose and
necropsied on trial day 49 (21 DPC). The total extent of macroscopic lung lesions
(ranging from 0 to 100%) was estimated and scored. Additionally, the sizes of
lymph nodes, ranging from 0 (normal) to 3 (four times the normal size), were
estimated and recorded (14). Lungs were insufflated with fixative as previously
described (6). Sections of lymph nodes (superficial inguinal, mediastinal, tra-
cheobronchial, and mesenteric), tonsil, thymus, ileum, kidney, colon, spleen, and
liver were collected at necropsy, fixed in 10% neutral-buffered formalin, and
routinely processed for histological examination.
Histopathology. Microscopic lesions were evaluated by a pathologist blinded
to the group designation of animal tissues. Sections were scored for the presence
and severity of interstitial pneumonia, ranging from 0 (normal) to 6 (severe
diffuse) (6). Sections of heart, liver, kidney, ileum, and colon were evaluated for
the presence of lymphohistiocytic inflammation and scored from 0 (none) to 3
(severe). Lymphoid tissues, including lymph nodes (tracheobronchiolar, mesen-
teric, mediastinal, superficial inguinal, and external iliac), tonsil, and spleen, were
evaluated for the presence of lymphoid depletion, ranging from 0 (normal) to 3
(severe), and histiocytic inflammation and replacement of follicles, ranging from
0 (normal) to 3 (severe) (16). The overall microscopic lymphoid lesion score,
which accounts for lymphoid depletion, histiocytic inflammation, and PCV2
antigen present in lymphoid tissues, was calculated as previously described (16)
and ranged from 0 (normal) to 9 (severe).
Immunohistochemistry. Immunohistochemistry (IHC) for detection of PCV2-
specific antigen was performed on selected formalin-fixed and paraffin-embed-
ded sections of lymph nodes (superficial inguinal, mediastinal, tracheobronchial,
and mesenteric), tonsil, spleen, and thymus using a rabbit polyclonal antiserum
(21). PCV2 antigen scoring was done by a pathologist blinded to animal group
designation. Scores ranged from 0 (no signal) to 3 (more than 50% of lymphoid
follicles contained cells with PCV2 antigen staining) (16). The mean group score
was determined for each tissue and compared among groups.
Statistical analysis. Summary statistics were calculated for all groups to assess
the overall quality of the data, including normality. Continuous data collected
over time were analyzed using multivariate analysis of variance (ANOVA). If a
multivariate ANOVA was significant (P 0.05), a nonparametric Kruskal-Wallis
one-way ANOVA was done at each time point. If significant (P  0.05) differ-
ences were seen at a time point, pairwise Wilcoxon tests were used to assess
differences between groups (data were nonparametric). In order to summarize
and simplify the clinical observations, a response feature analysis and a chi-
square test were used. The clinical scores for each pig were reduced to one
weekly mean score, and the resulting values were subjected to statistical analysis.
Daily rectal temperature data were analyzed with response feature analysis on
average weekly temperature. Nonrepeated measures of necropsy and histopa-
thology data were assessed using a nonparametric Kruskal-Wallis one-way
TABLE 1. Study design summary
Group No. ofanimals Vaccination
a ELISA status,
day 0 (S/P ratio)b Challenge
c ELISA status,
day 28 (S/P ratio)b
VAC-NEG 9 Yes Negative (9/9) Yes Positive (6/9)
VAC-POS 21 Yes Positive (21/21) Yes Positive (17/21)
NVAC-CNEG 15 No Positive (12/15) Yes Negative (15/15)
NVAC-CPOS 15 No Positive (15/15) Yes Positive (15/15)
a Animals were vaccinated on trial day zero with Suvaxyn PCV2 One Dose (Fort Dodge Animal Health, Inc., Fort Dodge, IA).
b An S/P ratio of less then 0.3 was considered negative; pigs with an S/P ratio of 0.3 were considered positive.
c Inoculation with PCV2 on trial day 28.
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ANOVA. If this nonparametric ANOVA test was significant (P  0.05), then
pairwise Wilcoxon tests were used to assess differences between groups.
RESULTS
Clinical presentation. None of the pigs developed clinical
disease during the duration of the experiment. None of the
pigs developed fever, and the average daily rectal temperatures
were not significantly (P  0.57) different among the groups.
Similarly, the average daily weight gain did not significantly
(P  0.76) differ among the groups.
Macroscopic lesions. No remarkable gross lesions were ob-
served. Individual vaccinated and nonvaccinated pigs had mild
lung lesions characterized by failure of the lungs to collapse
and small, focal, cranioventral consolidated areas of pneumo-
nia. There was no significant (P 0.05) difference between the
groups for the mean size of lymph nodes.
Anti-PCV2 IgM antibody levels. The group mean anti-PCV2
IgM antibody levels are summarized in Fig. 1. The VAC-POS
group had significantly (P  0.01) higher IgM antibody levels
from trial days 21 to 35 than the NVAC-CPOS group. Assess-
ment of the IgM antibody levels between the VAC-NEG and
NVAC-CNEG groups indicated that the VAC-NEG group
had a significantly (P  0.01) higher IgM response than the
NVAC-CNEG group from days 14 to 35. On trial days 42 and
49 (7 and 14 DPC), these groups remained significantly (P 
0.01) different, but the IgM response was higher in the NVAC-
CNEG group. In order to assess the effect of maternal anti-
body on IgM response, the VAC-POS and VAC-NEG groups
were compared. On trial days 14 and 21, VAC-NEG pigs had
significantly (P  0.01) higher IgM responses.
Anti-PCV2 IgG antibody levels. The mean group anti-PCV2
IgG serum levels for trial day zero (0 DPV) to trial day 48 (21
DPC) are summarized in Fig. 2. To assess the effect of mater-
nal antibody on vaccination, the IgG levels in VAC-POS and
VAC-NEG animals were addressed on trial days 0, 7, 14, and
21. VAC-POS pigs had significantly (P  0.01) higher IgG
levels than VAC-NEG pigs from trial days 0 to 21. Following
challenge on day 28, no significant differences in IgG levels
were noted between the two groups. In nonvaccinated animals,
the IgG levels following challenge were significantly (P 0.01)
higher in NVAC-CPOS pigs compared to NVAC-CNEG pigs
from days 28 to 42. To address vaccine efficacy, VAC-POS
animals were next compared to NVAC-CPOS pigs. Results
indicated that VAC-POS animals had significantly (P  0.01)
higher IgG levels at trial days 42 and 49 (14 and 21 DPC) in
comparison to NVAC-CPOS animals. Additionally, VAC-
NEG animals had significantly (P  0.01) higher IgG levels on
trial days 28, 35, 42, and 49 in comparison to NVAC-CNEG
pigs.
Neutralizing antibodies. The group mean NA titers and
standard errors are presented in Table 2. In order to assess
maternal antibody effects on neutralizing antibody formation,
VAC-POS pigs were compared to VAC-NEG pigs. As ex-
pected, VAC-POS pigs had significantly higher NA levels on
days 0 and 14 (P 0.01 for both days) compared to VAC-NEG
animals. The data from the nonvaccinated animals were simi-
lar; NVAC-CPOS animals had significantly higher NA titers on
trial days 0 (P  0.01), 14 (P  0.03), and 28 (P  0.01)
compared to NVAC-CNEG pigs.
In order to assess the effects of vaccination, VAC-POS an-
imals were compared to NVAC-CPOS animals. Results of this
comparison indicated that these two groups were significantly
(P  0.04) different on day 14, with higher levels in the VAC-
POS pigs. Comparison of VAC-NEG to NVAC-CNEG ani-
mals indicated significantly higher NA levels in NVAC-CNEG
on day 0 (P  0.01) which were reversed on day 28, at which
point the VAC-NEG levels were significantly (P  0.01)
higher.
Incidence and amount of PCV2 DNA in serum. PCV2 DNA
was not detected in any of the serum samples on trial days 0, 7,
14, 21, or 28. The number of PCV2 genomic copies in serum
FIG. 1. Group mean optical density (OD) ratios and standard er-
rors for anti-PCV2 IgM antibody responses. Trial day 0  vaccination;
trial day 28  PCV2 challenge; trial day 49  necropsy.
FIG. 2. Group mean S/P ratios and standard errors for anti-PCV2
IgG antibody responses on different trial days. Trial day 0  vaccina-
tion; trial day 28  PCV2 challenge; trial day 49  necropsy.
TABLE 2. Log-transformed PCV2 neutralizing antibody titers
Group
Log-transformed group mean (SE) PCV2 NA
titer on trial daya:
0 14 28
VAC-NEG 1.36 (0.08)A 1.78 (0.13)A 2.85 (0.24)A
VAC-POS 2.51 (0.10)B 2.44 (0.10)B 2.41 (0.10)B
NVAC-CNEG 1.95 (0.06)C 1.74 (0.07)A,C 1.58 (0.14)C
NVAC-CPOS 2.71 (0.10)B 1.99 (0.18)A,D 2.45 (0.12)A,B
a Significantly different (P  0.05) group means within each column are con-
nected by different superscript letters (A, B, C, and D).
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was significantly reduced in VAC-POS pigs in comparison to
NVAC-CPOS pigs on day 35 (7 DPC) (P  0.04), on day 42
(14 DPC) (P  0.01), and on day 49 (21 DPC) (P  0.01) (Fig.
3). Additionally, VAC-NEG pigs had significantly (P  0.01)
fewer PCV2 genome copies compared to NVAC-CNEG pigs
on trial days 35, 42, and 49 (Fig. 3).
Microscopic lesions and IHC staining. Mean scores and
standard errors for lesions in lungs and lymphoid tissue sec-
tions are summarized in Table 3. Specific lymphoid tissue le-
sions (lymphoid depletion and histiocytic replacement) and
IHC scores are summarized in Table 4. Comparison of micro-
scopic lesions between VAC-POS and VAC-NEG groups re-
vealed no significant (P  0.28 for interstitial pneumonia; P 
0.93 for overall lymphoid lesions) differences. Comparison of
microscopic interstitial pneumonia scores revealed signifi-
cantly (P  0.02) less severe interstitial pneumonia in NVAC-
CPOS animals and NVAC-CNEG pigs. Additionally, a signif-
icant reduction in microscopic lung lesions (P  0.01) and
overall lymphoid lesions (P  0.01) was noted between VAC-
NEG and NVAC-CNEG animals, and there was a significant
(P  0.01) reduction in overall lymphoid lesions in VAC-POS
pigs compared to NVAC-CPOS pigs.
DISCUSSION
In order to determine whether passively acquired, mater-
nally derived PCV2 antibodies interfere with the efficacy of
vaccination against PCV2, colostrum-fed specific-pathogen-
free pigs originating from a PCV2-seropositive population
were used in this study. This ensured that the study population
contained pigs with and without maternal antibodies at the
time of vaccination and inoculation.
The study design included four groups. Due to the logistical
difficulties of finding sufficient numbers of PCV2-seronegative
animals, a vaccinated, nonchallenged group and a nonvacci-
nated, nonchallenged group were not included in the study.
While this is less than ideal, previous publications have pro-
vided evidence that PCV2 vaccination (with the live chimeric
PCV1-2 vaccine) is efficacious in the pig model using PCV2-
negative pigs and is not associated with microscopic lesions (4,
5). Evidence of naturally acquired PCV2 infection was lacking
in the animals studied in this trial, and PCV2 DNA was not
detected in any of the serum samples prior to trial day 35 (7
DPC). Microscopic lesions and PCV2 real-time PCR data
from the nonvaccinated groups are consistent with PCV2 in-
fection following the challenge on trial day 28.
Overall, in comparison to NVAC-CPOS pigs, VAC-POS
animals had significantly (P  0.01) lower microscopic lym-
phoid tissue lesion scores and significantly (P  0.05) fewer
PCV2 genomic copies following PCV2 challenge. These find-
ings confirm previous studies, which have indicated that vacci-
nation prevents microscopic PCV2-associated lesions and re-
duces PCV2 viremia (4, 5). Additionally, the anti-PCV2 IgG
levels in the VAC-POS animals increased between trial days 28
(challenge) and 35, while IgG levels in NVAC-CPOS animals
declined (Fig. 2). These results are consistent with the chal-
lenge acting as a booster to the previous vaccination in the
VAC-POS animals. There were no significant differences in
macroscopic lung lesions between VAC-POS and NVAC-
CPOS animals. This is likely due to the use of the single PCV2
challenge model, in which clinical signs and lung lesions are
FIG. 3. Log-transformed group means for PCV2 DNA copies per
ml of serum. Trial day 28  PCV2 challenge; trial day 49  necropsy.
Different letters correspond to significant (P  0.05) differences be-
tween groups for that trial day.
TABLE 3. Microscopic lesion scores for lung (interstitial
pneumonia) and lymphoid tissues (overall lymphoid severity)
Group
Mean (SE) scorea
Interstitial pneumoniab Overall lymphoid severityc
VAC-NEG 0.11 (0.11)A 0.48 (0.18)A
VAC-POS 0.38 (0.15)A 0.69 (0.22)A
NVAC-CNEG 0.87 (0.19)B 3.76 (0.58)B
NVAC-CPOS 0.27 (0.15)A 2.77 (0.51)B
a Significantly different (P  0.05) group means within each column are indi-
cated by different superscript letters (A or B).
b Possible scores for interstitial pneumonia ranged from 0 (normal) to 6
(severe diffuse interstitial pneumonia).
c The mean cumulative value from seven lymphoid tissues (tonsil, spleen, and
five lymph nodes) is reported (possible range, 0 to 9) and includes scores for
lymphoid depletion (possible range, 0 to 3), inflammation (possible range, 0 to
3), and the amount of PCV2 (possible range, 0 to 3). Possible cumulative scores
for overall severity included normal (score of 0), mild (score range, 1 to 3),
moderate (range, 4 to 6), and severe (range, 7 to 9).
TABLE 4. PCV2 immunohistochemistry, lymphoid depletion, and
histiocytic replacement scores in selected lymphoid tissues
Tissue and
test
Mean (SE) scoreb for vaccination group
VAC-NEG VAC-POS NVAC-CNEG NVAC-CPOS
Lymph nodes
IHCa 0.00 (0.00)A 0.19 (0.15)A 1.67 (0.27)B 1.00 (0.22)B
LDc 0.44 (0.17)A 0.43 (0.13)A 1.73 (0.28)B 1.33 (0.27)B
HRc 0.11 (0.11)A 0.29 (0.12)A 1.67 (0.25)B 1.13 (0.24)B
Tonsil
PCV2 IHCa 0.00 (0.00)A 0.10 (0.10)A 0.60 (0.19)B 0.53 (0.17)A,B
LDc 0.11 (0.11)A,B 0.00 (0.00)B 0.40 (0.16)A 0.27 (0.15)A
HRc 0.00 (0.00)A 0.05 (0.05)A 0.53 (0.22)A 0.27 (0.15)A
Spleen
PCV2 IHCa 0.00 (0.00)A,B 0.10 (0.10)B 0.47 (0.13)C 0.33 (0.13)A,C
LDc 0.11 (0.11)A 0.14 (0.08)A 0.80 (0.17)B 0.87 (0.19)B
HRc 0.11 (0.11)A,B 0.14 (0.10)B 0.80 (0.17)C 0.60 (0.21)A,C
a Scores ranged from 0 (no signal) to 3 (more than 50% of the lymphoid
follicles contained cells with PCV2 antigen staining).
b Significantly different (P 0.05) group means within each row are connected
by different superscript letters (A, B, or C).
c Scores ranged from 0 (normal) to 3 (severe). LD, lymphoid depletion; HR,
histocytic replacement.
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rarely seen. In contrast, significantly more severe microscopic
lesions were observed in VAC-POS animals compared to
NVAC-CPOS animals.
After PCV2 challenge, there were no significant differences
in severity of PCV2-associated microscopic lesions, anti-PCV2
IgG levels following challenge, levels of PCV2 viremia, or
amounts of PCV2 antigen in tissue sections between VAC-
NEG and VAC-POS pigs. These results suggest that the vac-
cine is equally effective in reducing PCV2-associated lesions
and viremia regardless of the level of passively acquired anti-
bodies at the time of vaccination. The only significant differ-
ences between VAC-POS and VAC-NEG animals included
the anti-PCV2 IgM levels and the NA titers. Specifically, the
IgM response in VAC-POS animals was significantly lower and
delayed by 1 week compared to VAC-NEG animals. One ex-
planation for the IgM response is that in animals which were
ELISA positive at vaccination, maternal antibody inhibited a
strong IgM response. The NA titers in this trial indicated that
vaccination induced an NA response in the VAC-NEG group.
In the VAC-POS group, we were unable to determine if the
NA response was consistent with vaccination or due to passive
maternal antibody (which likely contains NA). Therefore, the
ability of the vaccine to induce an NA response in the presence
of maternal antibodies warrants further investigation.
In contrast to the vaccinated animals, there were significant
differences between the NVAC-CNEG and NVAC-CPOS pigs
following challenge. As expected, the NVAC-CNEG animals
had more severe microscopic lung lesions and higher levels of
PCV2 viremia than the NVAC-CPOS animals. Additionally,
initial differences in anti-PCV2 IgG levels and differences in
NA titers were most likely due to the presence of passively
acquired maternal NA. Following challenge, IgG levels in the
NVAC-CNEG pigs increased, in contrast to the NVAC-CPOS
group. This was most likely due to maternal IgG inhibition in
animals which had received passive immunization.
PCV2 infection typically occurs at the mid- to late nursery
phase or early in the finisher phase of production in North
American swine production systems and, thus, vaccination
should occur several weeks prior to this stage of production.
The results from this study indicate that the PCV2 vaccine
used in this study is effective in reducing viremia and micro-
scopic lesions consistent with PCV2 infection, even when used
in pigs with passively acquired antibodies at the time of vacci-
nation. This suggests that practitioners can recommend the use
of this PCV2 vaccine on pigs at an early age, such as around 26
days old, and well ahead of typical PCV2 exposure.
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